JUBLPHARMA · Healthcare
Jubilant Pharmova Ltd. reported revenue of ₹1,929 cr for January to March 2025, +9.7% on the year and +5.9% on the quarter. It is the highest quarterly revenue in the last 8 quarters on record. Over the last four quarters revenue comes to ₹7,235 cr, +7.9% on the four before.
Operating profit (EBITDA) was ₹345 cr, a margin of 17.9%, +248 bps on the year and +213 bps on the quarter. It is the widest margin of the last 8 quarters (range 10.6% to 17.9%). Operating costs grew +6.5% against revenue growth of +9.7%, so more of each rupee of sales reached operating profit.
The company swung to a net profit of ₹151 cr from a loss of ₹62.0 cr a year earlier, with earnings per share of ₹9.64. The tax rate of 27% is in line with its recent average. Profit over the last four quarters totals ₹836 cr, +1,061.1% on the four before.
On earnings per share of ₹52.68 over the last four quarters, the stock at ₹964.10 trades at 18.3 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Turned profitable from a loss a year ago.
Source: Quarterly statements
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,680 cr | ₹1,677 cr | ₹1,759 cr | ₹1,732 cr | ₹1,752 cr | ₹1,822 cr | ₹1,929 cr | ₹1,901 cr | ₹1,966 cr | ₹2,122 cr | ₹2,290 cr | ₹2,229 cr |
| YoY | — | — | — | +9% | +4% | +9% | +10% | +10% | +12% | +16% | +19% | +17% |
| EBITDA margin | 14.4% | 13.0% | 15.4% | 14.5% | 16.5% | 15.8% | 17.9% | 15.3% | 17.3% | 13.6% | 14.8% | 11.1% |
| Other income, % of PBT | 19% | 49% | — | 82% | 6% | −8% | 4% | 8% | 2% | −20% | 6% | 23% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 37% | 34% | — | 4% | 29% | 23% | 27% | 34% | 37% | 40% | 32% | 35% |
| Net profit | ₹62.0 cr | ₹66.0 cr | −₹62.0 cr | ₹482 cr | ₹102 cr | ₹101 cr | ₹151 cr | ₹102 cr | ₹120 cr | ₹56.0 cr | ₹119 cr | ₹56.0 cr |
| YoY | — | — | — | +7,933% | +65% | +53% | — | −79% | +18% | −45% | −21% | −45% |
| Core profit YoY | — | — | — | +463% | +72% | +169% | +103% | +58% | +37% | −20% | −16% | −54% |
| EPS | ₹3.92 | ₹4.19 | −₹3.68 | ₹30.26 | ₹6.45 | ₹6.33 | ₹9.64 | ₹6.46 | ₹7.55 | ₹3.51 | ₹7.50 | ₹3.55 |
| Flags | · | 2 | · | 3 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 1 | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Jubilant Pharmova Ltd. reported revenue of ₹1,929 cr (+9.7% on the year) and net profit of ₹151 cr (— on the year) for January to March 2025.
Profit before other income, exceptional items and tax moved +103.1% on the year, against — for reported profit.
None of the 6 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.